Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 226

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 226
---
 revenues, expenses and cash flows at the average exchange rate in effect for the respective period and equity transactions at historical exchange rates. Translation gains and losses are included in the cumulative foreign currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss.
 
 
F-12
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
The change in the presentation currency resulted in the following impact on the consolidated statement of financial position.
  Schedule of change in the presentation currency
 
                     Previously reported in CA$ December         Presentation currency change          Reported in US$ December 31,    
                                   31, 2023                                                                        2023                
---------------------------------------------------------------------------------------------------------------------------------------
                    $                                          $                                     $                                 
Total assets                                       31,446                               (7,701   )                            23,745   
Total liabilities                                   3,591                                 (881   )                             2,710   
Total equity                                       27,855                               (6,820   )                            21,035   

                     Previously reported in CA$ December         Presentation currency change          Reported in US$ December 31,    
                                   31, 2022                                                                        2022                
---------------------------------------------------------------------------------------------------------------------------------------
                    $                                          $                                     $                                 
Total assets                                       37,734                               (9,894   )                            27,840   
Total liabilities                                   5,445                               (1,427   )                             4,018   
Total equity                                       32,289                               (8,466   )                            23,823   

F-13
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
The change in the presentation currency resulted in the following impact on the consolidated statement of (loss) income.
 

                        Previously reported in CA$ December          Presentation currency change          Reported in US$ December 31,     
                                      31, 2023                                                                         2023                 
--------------------------------------------------------------------------------------------------------------------------------------------
                       $                                           $                                     $                                  
Revenues                                               9,633                                (2,490